Key Partnerships and Facility Expansion are Expected to Drive the Global Cell and Gene Therapy Manufacturing Services Market

The global cell and gene therapy manufacturing services market is anticipated to grow significantly at a CAGR of nearly 11.5% over the forecast period (2021-2027).  The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships and collaborations, mergers and acquisitions, geographical expansion, new product launches, and product innovation to remain competitive in the marketplace. For instance, in 2021, Charles River Laboratories acquired a cell & gene therapy contract development and manufacturing organization (CDMO) Cognate BioServices. The acquisition was intended to increase its cell and gene therapy manufacturing capabilities. 

Browse the full report description Global Cell and Gene Therapy Manufacturing Services Market Size, Share & Trends Analysis Report, By Therapy (Cell Therapy and Gene Therapy) By Scale (Pre-commercial/ R&D Scale Manufacturing, Commercial-Scale Manufacturing), By Indication (Cancer, CVD, Orthopedic, Infectious Diseases, and Others) By End-User (Pharmaceutical and Biotechnology Companies, and Academic and Research Institutes) Forecast Period, 2021-2027 at https://www.omrglobal.com/industry-reports/cell-and-gene-therapy-manufacturing-services-market

In addition to this, in 2021, Thermo Fisher Scientific Inc. acquired Henogen S.A., Novasep's viral vector manufacturing business in Belgium, for approximately $859.7 million. This acquisition is expected to increase its presence in the cell & gene therapy manufacturing therapy market. Further, in 2019, Thermo Fisher Scientific Inc. acquired Brammer Bio, a company involved in viral vector manufacturing for gene and cell therapies, for $1.7 billion.

Apart from this, FUJIFILM Cellular Dynamics opened a $21 million cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products in 2021. Further, Anemocyte announced itself as the first BMO (Biotech Manufacturing Organization) in the field of cell and gene therapies. In addition to building 2000 sq. meters of GMP and GMP-compliant facilities for the production of ATMP’s, its FLYn’ICE project is using drones equipped with cryogenic pods to achieve temperature-controlled transit of cell and gene therapies. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- by Therapy, Scale, Indication, and End-User. 
• Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
• Competitive Landscape-  Thermo Fisher Inc, Merck KGaA, and F. Hoffmann-La Roche Ltd. among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cell and Gene Therapy Manufacturing Services Market – Segmentation

By Therapy 

• Cell Therapy
• Gene Therapy

By Scale 

• Pre-commercial/ R&D Scale Manufacturing
• Commercial Scale Manufacturing

By Indication

• Cancer
• CVD
• Orthopedic 
• Infectious Diseases
• Others 

By End-User 

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

Global Cell and Gene Therapy Manufacturing Services Market – Segmentation by Region